Differential (Click to cross reference) adverse drug reaction algorithm andexanet anticoagulant, complications of anticoagulant, discontinuation anticoagulant, reversal of anticoagulant, treatment anticoagulant, treatment in CVD apixaban cerebrovascular accident cerebrovascular accident, acute management of cerebrovascular accident, thrombolytic agents in treatment ciraparantag coagulopathy complications controversies in neurology cost coumarin dabigatran efficacy endovascular therapy facial nerve palsy factor Xa inhibitor fibrinolytic agents fibrinolytic agents, complications fibrinolytic therapy, selection criteria hemostatic therapy idarucizumab INR values intracerebral hemorrhage intracerebral hemorrhage, progression of intracerebral hemorrhage, volume mortality non-vitamin K antagonist oral anticoagulants platelet inhibiting drugs prothrombin complex concentrate reperfusion review article rivaroxaban safety thrombectomy thrombolysis, mechanical tissue plasminogen activator, intravenous treatment of neurologic disorder vitamin K

Showing articles 0 to 10 of 10 Administering Thrombolysis for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants JAMA Neurol 78:515-518, Seiffge, D.J.,et al, 2021 Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke Stroke 51:1616-1619, Beharry, J.,et al, 2020 Stroke Reperfusion Therapy Following Dabigatran Reversal with Idarucizumab in a National Cohort Neurol 94:e1968-e1972, Barber, P.A.,et al, 2020 Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage Stroke 50:529-536, Bower, M.M.,et al, 2019 Management of Bleeding in Patients Taking Oral Anticoagulants JAMA 319:2032-2033, Anderson, I.,et al, 2018 Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke Stroke 49:2237-2240, Jin, C.,et al, 2018 Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents Stroke 48:1432-1437, Steiner, T.,et al, 2017 Idarucizumab for Dabigatran Reversal - Full Cohort Analysis NEJM 377:431-441, Pollack, C.V.,et al, 2017 Idarucizumab for Dabigatran Reversal NEJM 373:511-520, Pollack, C.V.,et al, 2015 FDA Approves Praxbind, the First Reversal Agent for the Anticoagulant Pradaxa JAMA 314:2227, , 2015 Showing articles 0 to 10 of 10